Clinical trials: HES - Hypereosinophilic Syndrome
EGPA - Eosinophilic Granulomatosis With Polyangiitis, HES - Hypereosinophilic Syndrome
The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome
The purpose of this study is to collect clinical, laboratory, and instrumental data from patients with eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome, which will then be analyzed using artificial…
- Trial name
- NCT07275190
- Testing
- Blood draw for the laboratory assessment
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Asthma; Eosinophilic
The Influence of Mepolizumab on Structural and Inflammatory Cells in Severe Eosinophilic Asthma
The IRIS study aims to investigate the way Mepolizumab affects the structure of the airway cells in patients with Severe Eosinophilic Asthma and how the immune function of these cells changes with treatment.
- Trial name
- IRIS (NCT05144087)
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Asthma; Eosinophilic
Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma
The purpose of this phase III Study is to demonstrate the efficacy of at least one dose of CHF 6532 on moderate and severe asthma exacerbations rate compared to placebo.
- Trial name
- PERSEA (NCT04049175)
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Bulgaria
- Volunteers
- 810 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Rhinosinusitis With Nasal Polyps, Severe Eosinophilic Asthma
Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
The goal of this observational study is to learn about clinical and functional outcomes in patients with Chronic rhinosinusitis with nasal polyps and comorbid Severe Eosinophilic Asthma and patients with Chronic rhinosinusitis…
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps, Severe Eosinophilic Asthma, Chronic Rhinosinusitis Without Nasal Polyps
- Trial name
- MepoRiNaPAs (NCT06069310)
- Testing
- Mepolizumab 100 MG
- Where
- 2 sites in Greece
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Eosinophilic Asthma, Asthma; Eosinophilic
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
- Conditions
- Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
- Trial name
- EXHALE-3 (NCT05813288)
- Testing
- Dexpramipexole Dihydrochloride
- Where
- 282 sites in United States, Argentina and 24 more
- Volunteers
- 654 people
- Sponsor
- Areteia Therapeutics
Asthma
A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma
This study will assess the efficacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.
- Trial name
- NCT05528679
- Testing
- 610 100mg, 610 300mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Hypereosinophilic Syndrome, Systemic Mastocytosis
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
This trial is for various types of malignancies which may depend on certain enzymes (tyrosine kinases) for growth. The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the…
- Conditions
- Hypereosinophilic Syndrome, Systemic Mastocytosis, Chronic Myelomonocytic Leukemia, Dermatofibrosarcoma
- Trial name
- NCT00171912
- Testing
- imatinib mesylate
- Where
- Australia
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Eosinophilic Asthma, EGPA - Eosinophilic Granulomatosis With Polyangiitis
Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
Introduction: The etiology and therapy of eosinophilic lung diseases are still poorly understood. For individual forms of disease, such as eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA), new…
- Conditions
- Eosinophilic Asthma, EGPA - Eosinophilic Granulomatosis With Polyangiitis, Samter Triad, HES - Hypereosinophilic Syndrome
- Trial name
- PROMETHEos (NCT04538937)
- Testing
- no intervention
- Where
- Austria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Asthma; Eosinophilic
Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion
Unicentric prospective real life study designed to analyse the efficacy of Dupilumab to reduce bronchial inflammation of asthma measured by inflammatory cell counts obtained in induced sputum and other related characteristics…
- Trial name
- DEBORA (NCT05787678)
- Testing
- Dupilumab
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Asthma; Eosinophilic
Patients With Severe Eosinophilic Asthma Treated With Benralizumab
Retrospective, multicenter, routine clinical practice study with consecutive inclusion of adult patients with severe eosinophilic asthma receiving benralizumab treatment.
- Trial name
- Asthma (NCT05078281)
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Primary Myelofibrosis, Polycythemia Vera
Myeloproliferative Neoplasms (MPNs) Patient Registry
The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.
- Conditions
- Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Mastocytosis
- Trial name
- NCT02760238
- Testing
- Observational
- Where
- Canada
- Volunteers
- 5,000 people
- Sponsor
- University Health Network, Toronto
Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis
European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank
Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of…
- Conditions
- Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis, Pulmonary Eosinophilia, Pulmonary Fibrosis
- Trial name
- chILD-EU (NCT02852928)
- Where
- 3 sites in Germany, Turkey (Türkiye) and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Matthias Griese
Asthma
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics.
- Trial name
- CHINOOK (NCT03953300)
- Testing
- Benralizumab
- Where
- 35 sites in United States, Canada and 3 more
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Severe Eosinophilic Asthma
Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
Observational, retrospective study in adults (≥18 years) with severe asthma (maintenance treatment with high dose inhaled corticosteroids combined with long-acting agonist β2) and eosinophilic phenotype, who at the discretion of…
- Trial name
- ORBE (NCT04126499)
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia
Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
The study was performed to assess: 1) clinical activity of Imatinib in patients with HES, CEL and CIH; 2) correlation between Imatinib activity and specific disease subtype; 3) long-term outcome of HES, CEL and CIH patients…
- Conditions
- Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia, Chronic Idiopathic Hypereosinophilia
- Trial name
- NILG-HES1-03 (NCT00787384)
- Testing
- Imatinib
- Where
- 4 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Northern Italy Leukemia Group
Asthma
A Study of Depemokimab in Participants of 6 to 11 Years of Age
This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age.
- Trial name
- GLIDE (NCT07671001)
- Testing
- Depemokimab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Hypereosinophilic Syndrome
Eosinophilia Diagnosis
Eosinophilia, defined by a blood eosinophil granulocytes rate greater than 500 / mm3, is frequently encountered in internal medicine.
- Trial name
- EOSINOPHILIM (NCT02581514)
- Testing
- Scheduled exams and diagnosis
- Where
- France
- Volunteers
- 53 people
- Sponsor
- University Hospital, Limoges
Asthma; Eosinophilic
Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma
The primary objective of the study is to measure the effect of mepolizumab on declines in oral corticosteroid therapy (prednisolone or prednisone) in patients with severe eosinophilic asthma.
- Trial name
- Mepolizumab (NCT03453021)
- Testing
- Mepolizumab
- Where
- France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Grenoble
Eosinophilic Asthma
Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma
This is a proof of concept study designed to assess the effects of a single intravenous dose of etokimab compared to placebo in adult participants with severe eosinophilic asthma.
- Trial name
- NCT03469934
- Testing
- Etokimab
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- AnaptysBio, Inc.
Asthma
Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
Primary objective of the study is to evaluate whether patients with severe eosinophilic asthma who have received long-term treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to…
- Trial name
- NCT02555371
- Testing
- Mepolizumab 100mg
- Where
- 73 sites in United States, Argentina and 12 more
- Volunteers
- 306 people
- Sponsor
- GlaxoSmithKline